Conventional treatment for non-Hodgkin lymphoma for the CHOP

Document Type

News Article

Department

Ophthalmology

Abstract

Adults with newly diagnosed, aggressive non-Hodgkin lymphoma who receive intensive chemotherapy plus haemopoietic stem-cell transplantation have a better 5 year event-free survival than do patients who receive CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone; N Engl J Med 2004; 350: 1287–95). “Our findings are important because they show that CHOP can no longer be regarded as the standard treatment for such patients”, explains Noel Milpied (University Hospital of Nantes, France).

Publication (Name of Journal)

Lancet Oncology

Link to Full Text

Share

COinS